Towards widespread clinical application of blood-based diagnostic tools.
The European Liquid Biopsy Academy (ELBA) project is an Innovative Training Network (ITN), funded under the European Commission’s Marie Sklodowska-Curie Programme, aiming to move the promising technology of liquid biopsies out of its infancy and bring it to the clinic with a further focus on Non-Small Cell Lung Cancer (NSCLC) early diagnosis. Liquid biopsies offer a minimally invasive, safe, and sensitive alternative or complementary approach for tissue biopsies, which can be a game-changer in cancer management.


Platelets

cfDNA

Circulating
tumor cells

Extracellular
vesicles
Blood is proven to be a valuable medium of biosources. Blood tests can potentially provide extensive information on the molecular landscapes of cancer. Currently, blood-based biopsy measurements focus on four main biosources.
THE TEAM

Biomarker discovery and assay development

Data analysis
and integration

Diagnostic tests standardization

Clinical
implementation
What's new

ELBA newsletter Spring Edition
Best suite for your small startup business lorem ipsum dolor sit amet consiquest.

Job Opportunity
Research Associate, Circulating cell-free tumour DNA analysis for earlier detection (Molecular and Computational Diagnostics Group).

H2020 MSCA - Innovative Training Networks
Research Associate, Circulating cell-free tumour DNA analysis for earlier detection (Molecular and Computational Diagnostics Group).